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Summary
Background The prevalence of dementia is of interest worldwide. Contemporary estimates are needed to plan for 
future care provision, but much evidence is decades old. We aimed to investigate whether the prevalence of dementia 
had changed in the past two decades by repeating the same approach and diagnostic methods as used in the Medical 
Research Council Cognitive Function and Ageing Study (MRC CFAS) in three of the original study areas in England.
Methods Between 1989 and 1994, MRC CFAS investigators did baseline interviews in populations aged 65 years and 
older in six geographically deﬁ ned areas in England and Wales. A two stage process, with screening followed by 
diagnostic assessment, was used to obtain data for algorithmic diagnoses (geriatric mental state–automated geriatric 
examination for computer assisted taxonomy), which were then used to estimate dementia prevalence. Data from 
three of these areas—Cambridgeshire, Newcastle, and Nottingham—were selected for CFAS I. Between 2008 and 
2011, new ﬁ eldwork was done in the same three areas for the CFAS II study. For both CFAS I and II, each area needed 
to include 2500 individuals aged 65 years and older to provide power for geographical and generational comparison. 
Sampling was stratiﬁ ed according to age group (65–74 years vs ≥75 years). CFAS II used identical sampling, approach, 
and diagnostic methods to CFAS I, except that screening and assessement were combined into one stage. Prevalence 
estimates were calculated using inverse probability weighting methods to adjust for sampling design and non-
response. Full likelihood Bayesian models were used to investigate informative non-response.
Findings 7635 people aged 65 years or older were interviewed in CFAS I (9602 approached, 80% response) in 
Cambridgeshire, Newcastle, and Nottingham, with 1457 being diagnostically assessed. In the same geographical 
areas, the CFAS II investigators interviewed 7796 individuals (14 242 approached, 242 with limited frailty 
information, 56% response). Using CFAS I age and sex speciﬁ c estimates of prevalence in individuals aged 65 years 
or older, standardised to the 2011 population, 8·3% (884 000) of this population would be expected to have dementia 
in 2011. However, CFAS II shows that the prevalence is lower (6·5%; 670 000), a decrease of 1·8% (odds ratio for 
CFAS II vs CFAS I 0·7, 95% CI 0·6–0·9, p=0·003). Sensitivity analyses suggest that these estimates are robust to 
the change in response.
Interpretation This study provides further evidence that a cohort eﬀ ect exists in dementia prevalence. Later-born 
populations have a lower risk of prevalent dementia than those born earlier in the past century.
Funding UK Medical Research Council.
Introduction
Dementia is a topic of international concern.1 Govern-
ments worldwide want to commit to action, including 
primary prevention (reduction of risk factors), secondary 
prevention (detection of proven prodromal and pre clinical 
states, during which early intervention has proved better 
than usual presentation), and tertiary prevention (best 
possible care for individuals with manifest dementia). 
This attention has been driven by epidemiological evi-
dence, for existing populations and projected into the 
future,2 combined with increased societal concern.3 
Generation of such epidemiological evidence is chal-
lenging. Population-based prevalence studies involve the 
identiﬁ cation or creation of true population sampling 
frames—including individuals living in care homes—and 
recruitment of communities and individuals to take part 
in the detailed assessments that are needed for a robust 
diagnosis. Prevalence studies detect unrecognised cases 
and those previously recognised by the family or health-
care and social-care services.
There has been an increase in epidemiological dementia 
research since the 1980s, with attempts at harmonisation 
across geographical areas, using common methods and 
diagnostic criteria. The estimates from these studies have 
been the basis of Delphi and other reviews.1,2,4,5 These 
estimates have been used to update projections of present 
and future demand for dementia-care services.1 Carers 
and charitable organisations have exerted pressure on 
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policy makers, resulting in increased investment in 
studies of prevalence and incidence in countries of 
lower and middle income, and development of dementia-
speciﬁ c services and research policy in higher income 
countries. However, despite an emphasis on investment 
in research investigating the detailed biological under-
pinnings of neurodegenerative disorders, few new studies 
have examined potential changes in the prevalence of 
dementia across time in speciﬁ c age groups.6–8 Govern-
ments and policy makers need accurate contem poraneous 
data, but the estimates for the UK and those widely used 
for estimation in higher income countries are now 
20 years old.9,10 
The prevalence of dementia in the population might be 
subject to change. Factors that might increase prevalence 
include: rising prevalence of risk factors, such as physical 
inactivity, obesity, and diabetes; increasing numbers of 
individuals living beyond 80 years with a shift in 
distribution of age at death;11 persistent inequalities in 
health across the lifecourse;12 and increased survival after 
stroke and with heart disease. By contrast, factors that 
might decrease prevalence include successful pri mary 
prevention of heart disease, account ing for half the 
substantial decrease in vascular mortality,13 and increased 
early life education, which is associated with reduced risk 
of dementia.14
Few studies can examine change over time. Studies 
based on routine data obtained over decades in the USA 
have hinted at reductions in dementia and severe 
cognitive impair ment,15,16 as have single-site studies in 
Europe;6–8,17 however, there is some conﬂ icting evidence 
from Asia.18 This optimism has been tempered because 
of the widely diﬀ ering methods of these studies: from 
population identiﬁ cation and health-care access to 
potentially subtle changes in diagnostic and sampling 
methods and limitations of analytical approaches.
The ﬁ rst UK Cognitive Function and Ageing Study 
(CFAS), known as the Medical Research Council (MRC) 
CFAS, began in 1989. One of a suite of European 
prevalence and incidence studies (forming the 
EURODEM collaboration),19 it was designed to test for 
geographical diﬀ erences within the UK, across 
populations with widely varying charac teristics, including 
vascular health. No consistent diﬀ erences were identiﬁ ed 
across Europe or within the UK.19 MRC CFAS examined 
populations in six geo graphical areas, with samples 
taken from the entire resident population, including 
those in care homes, and common diagnostic methods 
(ﬁ ve areas had identical methods). The response was 
about 80%. Prevalence and incidence estimates from 
MRC CFAS have been used extensively for national and 
international purposes.5,9,20
Since these European studies were initiated there has 
been much work in genetics, biology, and imaging. New 
investigations and classiﬁ cations have been introduced, 
including the widespread uptake of clinical criteria for an 
intermediate stage of cognition with increased risk of 
dementia progression (mild cognitive impairment), 
creating an unstable diagnostic environment. In most 
epidemiological studies since the late 1990s, starting in 
the USA, a consensus multidisciplinary diagnostic pro-
cess has been used to agree diagnostic criteria, them-
selves in a state of ﬂ ux.21 It is highly likely that changes in 
diagnostic criteria and the increased recognition of mild 
cognitive impairment as a new early preclinical diagnosis 
has led to shifting boundaries, such that it might be 
diﬃ  cult to compare old estimates with new ones. CFAS 
has the potential to allow such a comparison over time.
A new generation study, CFAS II, was designed and 
funded to test whether the prevalence of dementia (and 
incidence of dementia in due course) had changed from 
1991 to 2011.
Methods
Setting, study design, and participants
Between 1989 and 1994, the MRC CFAS investigators did 
baseline interviews in populations aged 65 years and 
older in six geographical areas in England and Wales. A 
two stage process, with screening followed by diag nostic 
assessment, was used to estimate dementia prevalence. 
Data from three of the English areas of MRC CFAS—
Cambridgeshire, Newcastle, and Nottingham, where 
interviews were done between Dec 19, 1990, and July 6, 
1993— were selected to provide CFAS I estimates. 
Between Nov 13, 2008, and Oct 25, 2011, we did new 
ﬁ eldwork in the same geographical areas to provide 
CFAS II estimates, which could be directly compared 
with CFAS I. These areas were selected to provide a 
geographical spread, including a rural area.
CFAS I and CFAS II had identical designs and 
methods, apart from a change from a two-stage design 
with CFAS I to a one-stage design with CFAS II. In 
CFAS I, the ﬁ rst phase was a screening process, which 
identiﬁ ed a subset of individuals who underwent diag-
nostic assessment. CFAS II combined the screen ing 
and assessment phases. More details are provided in 
the protocol.
Both CFAS I and CFAS II drew on the UK system of 
primary care registration, which provides the most 
robust population base for sampling by age group for 
epidemiological studies in the UK. In both studies, the 
population for invitation to interview was randomly 
sampled from the same geographical areas. Each area 
needed to include 2500 individuals aged 65 years and 
older to provide power for geographical and gen erational 
comparison. Sampling was stratiﬁ ed according to age 
group (65–74 years vs ≥75 years; 1250 per stratum per 
area). We used oversampling to allow for losses (death, 
incorrect registration, ineligibility, general practitioner 
refusals, participant or gatekeeper refusal). The primary 
care practices screened records of patients in selected 
samples regularly for deaths and terminal illness. An 
introductory letter from the general prac titioner was 
followed by a visit by a named study interviewer. Fully 
For the CFAS II protocol see 
http://www.cfas.ac.uk/pages/
bcfasiisp/index.html
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informed written consent was sought, and when capacity 
was impaired procedures complied with the UK Mental 
Capacity Act 2005.
Procedures
For both CFAS I and CFAS II, we recruited local inter-
viewers from a range of backgrounds (those working 
with older people in the voluntary, health-care, and 
social-care sectors), and gave them identical training 
(overseen by one investigator) to deliver the standardised 
computerised interviews. This training consisted of an 
intense week-long course, with follow up practice until 
each interviewer achieved the necessary quality stan-
dards, with ongoing quality control. Interviewers visited 
residences up to three times, and whenever possible 
elicited a response from the intended respon dent. 
Individuals who had moved but remained within the 
geographical area were included for interview.
The CFAS I baseline interview included questions 
about sociodemographic characteristics, lifestyle, 
health, activities of daily living (basic and instrumental), 
cog nition, health-care and social-care contact, and medi-
cation. A sample of 20% of those who had a baseline 
interview, stratiﬁ ed to represent the entire cognitive 
spectrum, was invited for assessment with the geriatric 
mental state (GMS) examination, a standardised 
interview for ascertainment of dementia and other 
neuropsychiatric syndromes in the older population. 
This examination provided the data for the diagnostic 
algorithm, the automated geriatric examination for 
com puter assisted taxonomy (AGECAT; drawing on 
respon dent and observer ratings).22 For all these 
respondents we also requested an informant interview, 
which included more detail on the presence of 
symptoms and sympton duration. In CFAS II, a one-
stage interview was done, which integrated the 
CFAS I CFAS II*
Screening* Assessment†
Sex
Men 3045 (39%) 531 (38%) 3550 (44%) 
Women 4590 (61%) 926 (62%) 4246 (56%) 
Age group
65–69 years 1981 (25%) 310 (23%) 1939 (23%) 
70–74 years 1776 (23%) 320 (22%) 1874 (23%) 
75–79 years 1725 (22%) 263 (23%) 1623 (21%)
80–84 years 1308 (18%) 291 (20%) 1289 (17%)
85–89 years 615 (9%) 186 (9%) 769 (11%) 
≥90 years 230 (4%) 87 (3%) 302 (6%) 
Location
Cambridgeshire 2601 (34%) 465 (37%) 2558 (30%) 
Newcastle 2522 (33%) 499 (31%) 2616 (34%)
Nottingham 2512 (33%) 493 (32%) 2622 (35%)
Residential status‡
Community 7281 (95%) 1269 (95%) 7599 (97%)
Care homes 347 (5%) 183 (5%) 197 (3%)
Data are n (%). CFAS=Cognitive Function and Ageing Study. *Percentages 
back-weighted for non-response. †Percentages back-weighted for sampling 
design and non-response. ‡Residential status missing for seven individuals for 
CFAS I (of whom ﬁ ve were also assessed). 
Table 1: Demographic characteristics of individuals participating in 
screen and assessment (CFAS I) and interview (CFAS II) Figure 1: CFAS I and CFAS II age-specific dementia prevalence
CFAS=Cognitive Function and Ageing Study.
65–69 70–74 75–79 80–84 85–89 ≥90
0
5
10
15
20
25
30
35
40
Es
tim
at
ed
 p
re
va
le
nc
e 
in
 p
op
ul
at
io
n 
ag
ed
 6
5 
ye
ar
s a
nd
 o
ld
er
 (%
)
Age group (years)
CFAS I
CFAS II
CFAS I CFAS II*
N % (95% CI) N % (95% CI)
Men
65–69 years 145 1·7% (0·8–3·2) 968 1·2% (0·6–2·3)
70–74 years 146 2·2% (1·2–4·0) 903 3·0% (2·0–4·4)
75–79 years 107 5·7% (3·4–9·2) 756 5·2% (3·8–7·0)
80–84 years 74 14·6% (8·6–23·7) 540 10·6% (8·2–13·7)
85–89 years 48 19·8% (10·3–34·6) 273 12·8% (9·0–18·0)
≥90 years 11 68·2% (34·8–89·6) 85 17·1% (10·6–26·4)
Women
65–69 years 165 2·0% (1·0–3·8) 971 1·8% (0·9–3·6)
70–74 years 174 2·9% (1·7–5·0) 971 2·5% (1·6–3·9)
75–79 years 156 7·4% (3·7–14·6) 866 6·2% (4·5–8·4)
80–84 years 217 13·9% (9·7–19·4) 736 9·5% (7·3–12·3)
85–89 years 138 26·5% (18·1–37·1) 434 18·1% (14·5–22·2)
≥90 years 76 32·3% (21·7–45·0) 217 35·0% (28·4–42·3)
By sex, standardised to 2011 UK age structure
Men ·· 7·4% (5·7–9·1) ·· 4·9% (4·2–5·7)
Women ·· 9·4% (7·6–11·2) ·· 7·7% (6·8–8·5)
Total ·· 8·3% (7·0–9·6) ·· 6·5% (5·9–7·0)
By area, standardised to 2011 UK age structure 
Cambridgeshire ·· 6·7% (5·0–8·4) ·· 6·1% (5·1–7·1)
Newcastle ·· 8·3% (6·3–10·2) ·· 7·2% (6·2–8·3)
Nottingham ·· 10·2% (7·4–13·0) ·· 6·0% (5·0–6·9)
*76 individuals in CFAS II had unknown dementia status.
Table 2: Number with known dementia status and dementia prevalence
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screening and assessment phases of MRC CFAS to 
reduce analytical complexity and attrition. An informant 
inter view for those with a cog nitively impaired proﬁ le, 
and for a random selection of those without, was 
requested for 20% of the sample. The content of the 
interviews is provided on the CFAS website.
CFAS I and CFAS II used an algorithmic approach to 
diagnosis to provide consistency across area and time, 
eliminating the variability that has been shown with 
clinical diagnosis.23 The principle of the process is that 
data needed for diagnosis are collected in a standardised 
manner, and a diagnostic algorithm is then applied to 
these data. GMS-AGECAT diagnoses have been shown 
to be as reliable as those made by a range of clinicians 
and has been validated against clinical diagnoses of 
dementia made according to Diagnostic and Statistical 
Manual of Mental Disorders (DSM) IIIR criteria.22 This 
standard isation allowed a comparison of estimates with-
out the unknown bias introduced by recent shifts in 
clinical attitudes and practice. Missing data within an 
interview could prevent an algorithm diagnosis and for 
individuals with missing data, the same approach was 
taken for CFAS II as for CFAS I, which was a review of 
all available information by diagnostician (CB), applying 
DSM-IIIR criteria. Many of these individuals had severe 
cognitive impairment and were not able to respond to 
the interview questions.
Statistical analysis
We estimated prevalence using inverse probability weight-
ing methods (in Stata, version 12) that adjusted for non-
response (CFAS I and CFAS II) and study design selection 
(CFAS I). We calculated response by birth cohort and sex 
(CFAS I), and birth cohort, sex, care setting, and depri-
vation status of postcode (CFAS II), which were all factors 
that were known for the complete population, including 
those who did not take part. The eﬀ ect of response 
adjustment on CFAS I was slight, so we did not use a 
more complex adjustment. In CFAS II, individuals who 
needed informant (proxy) interview because of known 
dementia (or other severe frailty) were weighted separately 
to account for this additional information.
We standardised prevalence estimates by the UK age 
and sex distribution at the time of the ﬁ rst interviews 
(1991 for CFAS I, 2011 for CFAS II) using 5 year age 
bands; for CFAS I estimates were then also standardised 
to the 2011 distribution. Prevalence estimates from 
CFAS II were applied using the age and sex distribution 
to generate population levels of dementia for the UK. We 
tested area variation for both time periods, also taking 
into account deprivation, using postcode-level Townsend 
deprivation scores.24 Prevalence estimates by deprivation 
tertile, age, and sex were applied to the age and sex 
distribution of England’s upper tier local authorities (eg, 
counties or cities) to provide standardised estimates. 
Maps were drawn using quintiles of prevalence estimates.
We did a range of sensitivity analyses with inverse 
probability weighting methods and also using full 
likelihood Bayesian modelling (using WinBUGS 
software, version 1.4.3). Initially the inverse probability 
rates were checked against a similar model with missing 
interviews modelled using the same factors that 
generated the weight. We made further extensions to 
assume all individuals who did not respond had either a 
50% or 100% higher occurrence of dementia (informative 
missing); we also modelled diﬀ erent types of non-
response, with active refusal having lower dementia 
occurrence (20% lower), and increases in those who 
refused because they were too ill (100% higher) or who 
had a passive or proxy refusal (50% higher). These 
values were decided a priori on the basis of previous 
investigations of missing data.26 Further details of the 
methods are provided in the appendix.
CFAS I CFAS II
N* % (95% CI) N % (95% CI)
Men
Community
65–74 years 274 0·9% (0·5–1·8) 1859 1·8% (1·3–2·7)
75–84 years 166 8·1% (5·6–11·8) 1273 6·4% (5·2–8·1)
≥85 years 40 15·0% (7·1–29·0) 339 11·9% (8·6–16·3)
Overall ·· 4·4% (3·3–5·8) ·· 4·7% (4·1–5·7)
Standardised ·· 6·1% (4·1–8·1) ·· 4·2% (3·5–4·9)
Care homes
65–74 years 17 59·7% (33·8–81·1) 12 34·0% (7·3–56·5)
75–84 years 14 19·6% (5·6–50·2) 23 72·0% (44·6–87·0)
≥85 years 18 83·9% (52·5–96·1) 19 55·6% (31·5–77·4)
Overall ·· 51·3% (31·0–71·3) ·· 57·2% (39·8–68·7)
Standardised ·· 55·8% (45·6–65·9) ·· 46·2% (27·7–58·8)
Women
Community
65–74 years 329 2·1% (1·3–3·3) 1935 1·6% (1·2–2·6)
75–84 years 318 7·9% (5·1–12·1) 1563 5·9% (4·9–7·8)
≥85 years 142 19·0% (12·1–28·6) 560 17·0% (14·2–21·9)
Overall ·· 7·1% (5·3–9·4) ·· 6·0% (5·4–7·3)
Standardised ·· 6·7% (4·9–8·5) ·· 5·5% (4·7–6·3)
Care homes
65–74 years 9 41·5% (15·3–73·6) 7 90·2% (50·3–98·8)
75–84 years 55 62·7% (46·4–76·5) 39 76·0% (59·3–87·2)
≥85 70 56·4% (38·7–72·6) 91 71·1% (60·0–80·1)
Overall ·· 58·0% (45·9–69·2) ·· 73·4% (64·6–80·7)
Standardised ·· 55·9% (36·9–74·8) ·· 75·2% (58·6–91·7)
Total
Care homes
65–74 years ·· 52·9% (33·3–71·6) ·· 60·3% (35·9–80·5)
75–84 years ·· 51·4% (35·9–66·6) ·· 74·6% (61·3–84·5)
≥85 years ·· 60·8% (44·3–75·1) ·· 68·8% (58·7–77·5)
Overall ·· 56·4% (45·9–66·3) ·· 69·6% (62·0–76·2)
Standardised ·· 59·7% (48·9–70·4) ·· 64·6% (51·7–77·6)
*Residential status missing for ﬁ ve individuals  in CFAS I. 
Table 3: Number with known dementia status and dementia prevalence by age, sex, and residential status 
For the CFAS website see http://
www.cfas.ac.uk
See Online for appendix
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Role of the funding source
The funders are represented on the CFAS Management 
Committee and the Biological Resource Advisory Com-
mittee but they had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The ﬁ rst author had full access to all the data 
in the study and the corresponding author had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
In CFAS I, 7635 people aged 65 years and older were 
interviewed (9602 approached, 80% response) in 
Cambridgeshire, Newcastle, and Nottingham, with 
1457 being diagnostically assessed. In the same geo-
graphical areas, 7796 were interviewed for CFAS II 
(14 242 approached, 242 with limited frailty information, 
56% response). Thus, response was lower for CFAS II 
than for CFAS I. A comparison of the reasons for refusal 
suggests non-response across the cognitive spectrum, with 
reasons ranging from carers deeming an individual to be 
too frail to a lack of time. We identiﬁ ed some variation by 
area (appendix). Table 1 shows the numbers included 
within the analyses. As expected,27 there was a reduction in 
the proportion of the population to be approached residing 
in care settings (residential and nursing homes; 5% for 
CFAS I vs 3% for CFAS II; details in appendix).
Comparison of standardised prevalence across time 
showed a substantial decrease in prevalence of dementia 
(odds ratio [OR] CFAS II vs CFAS I was 0·7, 95% CI 
0·6–0·9, p=0·003, adjusted for age, sex, area, and 
deprivation status; table 2, ﬁ gure 1). Women had a 
consistently higher prevalence of dementia than men in 
all settings (table 3). The overall decrease was driven by 
non-care settings and was not noted within people in 
care settings, where prevalence increased (OR 1·7, 
95% CI 1·0–2·9, p=0·05; table 3). In CFAS I, the number 
of individuals with dementia in care settings represented 
34% of all dementia cases (29% men, 36% women). In 
CFAS II, despite higher dementia prevalence in care 
settings, the proportion of the population who had 
dementia and who lived in care had reduced slightly to 
29% overall (17% men, 35% women). This apparent 
paradox is because of the reduction in the proportion of 
the older population who now live in care settings.
The analysis shows marginal, non-signiﬁ cant, diﬀ er-
ences across the three areas. Any diﬀ erence disappears 
once area deprivation is taken into account (data not 
shown). However, ﬁ gure 2 shows that predicted prevalence, 
adjusted for age structures and deprivation, varies widely 
across the country and between men and women.
Using the age and sex speciﬁ c prevalence estimates 
from CFAS I in 1991, in the UK 664 000 individuals were 
expected to have dementia at that time. Taking into 
account only the eﬀ ects of population ageing, this 
number would now be expected to be 884 000. However, 
CFAS II estimates that the number of people with 
dementia in the UK in 2011 was 670 000, 214 000 fewer 
than population ageing alone would have predicted, a 
reduction of 24%.
As detailed in the Methods and appendix, we did various 
sensitivity analyses. Assuming that all individuals living 
in care settings who were selected to take part, but did not, 
Figure 2: Estimated dementia prevalence in the UK in 2011, by sex and local authority 
Men Women
3·30–4·32%
4·33–5·24%
5·25–6·38%
6·39–6·96%
6·97–8·38%
Prevalence
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had dementia did not increase the estimates (table 4). The 
full likelihood Bayesian model gave very similar estimates 
with the assumption of missing at random and the inverse 
probability weighting method. Scenarios for informative 
missingness models were created, which tested how 
extreme assumptions would need to be to approach the 
earlier estimates. These scenarios did increase the 
estimates (table 4) but no scenarios, decided a priori and 
improbably severe, increased the prevalence to that 
estimated 20 years ago. These scenarios were deemed 
improbably severe because interviewers made eﬀ orts to 
seek a direct refusal and when there was gatekeeping, the 
nature of the frailty of the respondent was apparent. Thus, 
although we have no direct information for these 
individuals, the refusal codes allow for testing of our 
assumptions (further information provided in appendix).
Discussion
This study provides compelling evidence of a reduction 
in the prevalence of dementia in the older population 
over two decades. On the basis of the age and sex speciﬁ c 
prevalence estimates from CFAS I, 664 000 individuals 
were estimated to have dementia in 1991. Taking into 
account only the eﬀ ects of population ageing, this 
number would now be expected to be 884 000. However, 
the results of CFAS II suggest that the number of people 
with dementia in 2011 was 670 000, which is 214 000 fewer 
than population ageing alone would have predicted—a 
reduction of 24%. However, the prevalence of dementia 
within care settings has increased from 56% to 70%. 
Prevalence varies according to deprivation indices 
and applying this  information to English localities 
shows substantial variation in expected prevalence of 
dementia (panel).
This evidence is based on repeated prevalence studies 
in randomly sampled older people living in the 
community or in care settings in three geographical 
areas of England. Dementia by age and sex shows the 
same patterns, but with lower point estimates. Prevalence 
has increased in care settings, which now contain a 
smaller proportion of the older population. Slight, non-
signiﬁ cant, geographical variation was noted in both 
CFAS I and CFAS II and is explained by strong 
deprivation eﬀ ects. The key features of CFAS II are that 
it was designed to examine cross-generational changes in 
dementia prevalence and related features, was done in 
several areas, was powered to detect changes, and had 
consistent methods and diagnostic procedures.
The studies had several limitations. There have been 
substantial changes in perceptions and attitudes to 
population-based research, with many more barriers for 
CFAS II, some of which are related to increased 
sensitivity about data protection. The accuracy of 
population registers is problematic in all areas. Reasons 
for non-response were not particularly diﬀ erent between 
these studies, but some reasons became more prominent, 
including both refusal by others for frail individuals, and 
refusal by very active individuals. There might have been 
further reasons that we could not observe or note. This 
reduction in response is a common theme in attempted 
population-based studies and has required detailed 
sensitivity analyses to assess its potential eﬀ ect.25 None of 
the sensitivity scenarios (table 4) resulted in higher esti-
mates of prevalence than those recorded 20 years ago, 
despite high prevalence of dementia being assumed in 
non-responders. The scenarios used, although based on 
knowledge of longitudinal attrition and drawing on as 
much information from the interviewers’ responses as 
possible, cannot replace high response rates.26 Other 
scenarios have been explored to investigate potentially 
higher prevalence of dementia within those who did not 
respond to the interview; however, to reach the prevalence 
of dementia estimated in CFAS I, for those aged 80 years 
or older, at least 50% of non-responders would have had 
Total Men Women Cambridgeshire Newcastle Nottingham
Prevalence Number Prevalence Number Prevalence Number
Main analysis 6·5% 670 000 4·9% 227 000 7·7% 443 000 6·1% 7·2% 6·0%
Dynamic population 6·6% 685 000 5·0% 230 000 7·9% 455 000 6·3% 7·3% 6·1%
All in care not seen have dementia 5·9% 598 000 4·8% 222 000 6·8% 396 000 5·4% 6·8% 5·6%
Simple MAR* 6·0% 625 000 4·8% 221 500 7·0% 404 000 5·3% 7·1% 5·5%
Type of refusal MAR* 6·0% 625 000 4·8% 221 000 7·0% 403 500 5·3% 7·1% 5·5%
All refusals at 50% increased risk of 
dementia*
7·7% 797 000 6·1% 279 000 8·8% 516 500 6·7% 9·0% 7·2%
All refusals at 100% increased risk of 
dementia*
8·5% 882 000 6·7% 309 000 9·9% 572 000 7·4% 10·0% 8·0%
Ill health at 100% increased risk, 
passive or proxy refusals at 50% 
increased risk, active refusals at 20% 
decreased risk*
6·9% 717 000 5·5% 253 000 8·0% 464 000 6·1% 8·1% 6·4%
Descriptions of scenarios are provided in Methods and appendix. MAR=missing at random. *Bayesian model.
 Table 4: Sensitivity analyses for eﬀ ect of sample non-response on estimate of dementia prevalence in 2011 
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to have had dementia, which is unlikely in view of the 
study design with face-to-face contact whenever possible 
and for most refusals.
Although the key methods were identical, CFAS I was a 
two-stage study whereas CFAS II was one-stage, a decision 
made on the basis of experience of both attrition between 
phases and complexity of analysis in longitudinal studies. 
Most estimates in the scientiﬁ c literature from two-stage 
studies do not fully take design features into account, 
leading to overoptimistic CIs, which do not account for 
the uncertainty introduced in multistage processes.30 Our 
CFAS I analyses do take these factors into account. 
CFAS II was designed to avoid this complexity while 
retaining the ability to compare with CFAS I.
The algorithmic diagnostic method was designed and 
introduced to provide consistency and reasonable validity 
compared with clinical classiﬁ cations, but became super-
seded by clinical consensus methods.31 Large-scale epi-
demiological studies are now revisiting the algo rithmic 
approach after many years of onerous multi disciplinary 
clinical consensus conferences.32 The chang ing nature of 
investigations without standardised cutoﬀ s or age norms, 
the absence of clear operational isation of changing 
criteria, the rise of the mild cognitive impairment clinical 
classiﬁ cation and, most recently, the discussion sur-
round ing DSM-5 create a very unstable environment to 
sustain constant consensus approaches.22 The eﬀ ects of 
these boundary and investigational changes are un-
known, and will aﬀ ect who and how much of the 
population is labelled with a diagnosis.33,34 These vari-
ations could act in both directions and could lead either 
to a reduction in the number of people given the full 
dementia diagnosis (with some being classiﬁ ed into the 
mild cognitive impairment categories), or an increase (as 
a result of investigations showing abnor malities, which 
in fact might be common in non-demented older people, 
reinforcing diagnosis). So, although the algorithmic 
approach can now be deemed either outdated or forward-
thinking,32 it has been held constant and is the only 
diagnostic method that can avoid the potential, unknown, 
biases noted previously, allowing for robust comparisons. 
The absolute numbers of people with dementia at any 
time point will be indicative of the diagnostic fashions of 
that era, a situation which compli cates epidemiological 
comparisons.
Our results suggest that the original intention of MRC 
CFAS, which was to provide a dedicated surveillance 
method to examine changes in dementia and related 
factors over time using constant methods and including 
the ability to incorporate recent diagnostic advances, 
should be actively pursued.2 Whether or not the gains 
that we have identiﬁ ed for the present older population 
will be borne out in later generations will probably 
depend on whether further improvements in primary 
prevention and eﬀ ective health care for disorders that 
increase the risk of dementia can be achieved, including 
addressing inequalities.35,36
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Panel: Research in context
Systematic review
We searched PubMed (up to July 11, 2013) with the search terms “dementia” or “Alzheimer’s 
disease” and “cohort change” or “time” or “trends”. No studies were excluded because of 
language or year, but only studies relating to time changes seen in the recent past were 
selected for inclusion in this report. Studies were generally single site, or of speciﬁ c age 
groups, or using diﬀ erent diagnostic criteria over time. No UK results were identiﬁ ed.
Interpretation
Results of a few studies6–8,15,16,28 have suggested that in higher income countries, the 
prevalence and inferred or measured incidence of dementia and severe cognitive 
impairment might have decreased. Our ﬁ ndings support these results and also show that 
there is measurable variation in the prevalence of dementia within England. The scale of 
the reduction that we identiﬁ ed is substantial and is in line with major reductions in risk 
factors in higher income countries, which have been modiﬁ ed by societal changes such as 
improvements in education, and prevention and treatment strategies in recent decades.29
Although many factors could have increased dementia prevalence at speciﬁ c ages (such as 
those associated with diabetes, survival after stroke, and vascular incidents), other factors, 
which could decrease prevalence, such as improved prevention of vascular morbidity and 
higher levels of education, seem to have had a greater eﬀ ect. Further work will be done to 
attempt to quantify some of these changes, but this analysis is beyond the scope of the 
present paper. CFAS I and CFAS II were designed to investigate generational change and 
provide contemporaneous estimates. In the UK, substantial evidence exsits for inequality 
in health, and the present ﬁ ndings suggest that some areas will have beneﬁ ted more than 
others from reduction in risk. Figure 2 shows that across England this variation, applied to 
local age structures, leads to diﬀ erences in expected prevalence by geography. The numbers 
with manifest dementia in the population for planning and policy analysis, according to our 
study methods, will need to be revised downwards. Prevalence in care settings has increased, 
but most individuals with dementia still live in the community.
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